Abstract
Existing quality of life instruments do not include adequate items to measure the side effects and putative benefits of hormonal treatments given in breast cancer. We report the development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT‐B) [1]. The FACT‐ES (FACT‐B plus ES) was tested initially on 268 women with breast cancer receiving endocrine treatments. Alpha coefficients for all subscales demonstrated good internal consistency (range α = 0.65–0.87). Test‐retest reliability of the ES indicated good stability (r = 0.93, p < 0.001). Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well‐being and fewer breast cancer concerns. Most frequently reported symptoms were loss of sexual interest (31%), weight gain (25%), and hot flushes (24%). Significant differences were found between treatment groups for hot flushes and vaginal dryness. Two assessments of the instrument's responsiveness to change were made; 32 women in a clinical trial of endocrine therapy and 18 women without breast cancer taking HRT completed the FACT‐ES at baseline, 4, 8, and 12 weeks. Trial patients reported significantly more symptoms at 8 and 12 weeks than at baseline. Women taking HRT reported significantly fewer or less severe symptoms than at baseline. In conclusion the FACT‐ES has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy.
Similar content being viewed by others
References
Brady MJ, Cella DF, Mo F, et al.: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol 15: 974–986, 1997
Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A(4): 576–588, 1996
Jonat W, Howell A, Blomqvist C, et al.: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3): 404–412, 1996
Couzi RJ, Helzlsouer K, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13: 2737–2744, 1995
Love RR, Cameron L, Connell BL: Symptoms associated with tamoxifen treatment in postmenopausal women. Archives Int Med 151: 1842–1847, 1991
Kornblith AB, Hollis DR, Zuckerman E: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11: 2081–2089, 1993
Hayes DF, Van Zyl JA, Hacking A: Randomized comparison of tamoxifen with two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566, 1995
Leonard RCF, Lee L, Harrison ME: Impact of side effects associated with endocrine treatments for advanced breast cancer: Clinicians' and patients' perceptions. The Breast 5: 259–264, 1996
Hopwood P: Living with advanced breast cancer: Development and application of a clinical checklist for patients on endocrine therapy. The Breast 7: 14–21, 1998
Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M: Measuring the impact of menopausal symptoms on quality of life. Br Med J 307: 836–840, 1993
Canney PA, Hatton MQF: The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 6: 297–299, 1994
Cella D: Manual for the Functional Assessment of Cancer Therapy (FACT) quality of life instrument (Version 4). Evanston Northwestern Healthcare, Evanston, II, USA, 1997
Streiner DL, Norman GR: Health Measurement Scales. Oxford University Press, New York, 1989
Nunnally JC: Psychometric Theory, 2nd edition. McGraw-Hill, New York, 1978
Cella DF, Bonomi AE, Lloyd SR, Tulskey DS, Kaplan E, Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199–220, 1995
Bonomi AE, Cella DF, Hahn EA, et al.: Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5: 309–320, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fallowfield, L.J., Leaity, S.K., Howell, A. et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B. Breast Cancer Res Treat 55, 187–197 (1999). https://doi.org/10.1023/A:1006263818115
Issue Date:
DOI: https://doi.org/10.1023/A:1006263818115